MDMA

Why MDMA-assisted psychotherapy may become an FDA-approved treatment for PTSD within 2 years

by

For peo­ple with post-trau­mat­ic stress dis­or­der, recall­ing mem­o­ries of phys­i­cal or sex­u­al assault, com­bat or dis­as­ter-relat­ed events can induce intense anx­i­ety or pan­ic attacks as well as debil­i­tat­ing flashbacks.

In the U.S., about 7% of peo­ple suf­fer from PTSD and lose an aver­age of about four work­ing days each month as a result. Trau­ma-spe­cif­ic psy­chother­a­py, like cog­ni­tive pro­cess­ing or “talk” ther­a­py, is the cor­ner­stone of treat­ment for PTSD. But for approx­i­mate­ly half of peo­ple, these tra­di­tion­al approach­es are inef­fec­tive at ful­ly address­ing PTSD symp­toms over the long term. Anti­de­pres­sant drugs are fre­quent­ly used if psy­chother­a­py fails, or in com­bi­na­tion with it, but the effects are usu­al­ly mod­est. [Read more…] about Why MDMA-assist­ed psy­chother­a­py may become an FDA-approved treat­ment for PTSD with­in 2 years

Study finds MDMA-assisted therapy to be safe and highly effective to treat severe PTSD

by

The First Phase 3 Suc­cess for Psy­che­delics Will Pave the Way for an Indus­try (Bar­ron’s):

Post-trau­mat­ic stress dis­or­der is a crip­pling, hard-to-treat psy­chi­atric afflic­tion. Amer­i­ca spends bil­lions of dol­lars year­ly just on the vet­er­ans who suf­fer from PTSD. So it’s heart­en­ing to see the report of a promis­ing new treat­ment, pub­lished Mon­day in Nature Med­i­cine. [Read more…] about Study finds MDMA-assist­ed ther­a­py to be safe and high­ly effec­tive to treat severe PTSD

Next: Psychedelic-assisted psychotherapy?

by

How ecsta­sy and psilo­cy­bin are shak­ing up psy­chi­a­try (Nature):

… The Impe­r­i­al study was one of a spate of clin­i­cal tri­als launched over the past few years using illic­it psy­che­del­ic drugs such as psilo­cy­bin, lyser­gic acid diethy­lamide (LSD) and MDMA (3,4‑methylenedioxymethamphetamine, also known as mol­ly or ecsta­sy) to treat men­tal-health dis­or­ders, gen­er­al­ly with the close guid­ance of a psy­chi­a­trist or psy­chother­a­pist. The idea has been around for decades — or cen­turies in some cul­tures — but the momen­tum has picked up dras­ti­cal­ly over the past few years as investors and sci­en­tists have begun to cham­pi­on the approach again. [Read more…] about Next: Psy­che­del­ic-assist­ed psychotherapy?

Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health

by

– Cred­it: Cell Reports 2018 23, 3170–3182DOI: (10.1016/j.celrep.2018.05.022). Copy­right © 2018 The Authors

Psy­che­delics in Neu­rol­o­gy: Poten­tial for Improv­ing Neu­ro­plas­tic­i­ty (Neu­rol­o­gy­Times):

“Back in the 1950s, research was prov­ing that psy­che­del­ic agents could be effec­tive in the treat­ment of var­i­ous neu­ropsy­chi­atric dis­or­ders. Unfor­tu­nate­ly, just as sci­ence was explor­ing their ben­e­fi­cial effects, the coun­ter­cul­ture was explor­ing and embrac­ing their effects. Slow­ly but sure­ly, psy­che­delics were asso­ci­at­ed with rebel­lious youth and the tumul­tuous anti-war move­ment. As a result, the gov­ern­ment shut down most of the research.

The 1990s saw renewed inter­est in psy­che­del­ic com­pounds as a means to address neu­ropsy­chi­atric dis­or­ders. Research explored the ben­e­fits of MDMA and ket­a­mine to treat mood dis­or­ders and post­trau­mat­ic stress dis­or­der. Now, a new study sheds even more light on the promise these agents might pro­vide. [Read more…] about Study: Psy­che­delics can pro­mote neur­al plas­tic­i­ty in the pre­frontal cor­tex and expand path­ways for men­tal health